| Literature DB >> 27642594 |
Zhu Chen1, Chunmei Li1, Caixia Yang1, Ronghua Zhao1, Xiaojian Mao1, Jie Yu1.
Abstract
Introduction. Raw and processed Notoginseng Radix Et Rhizome (NRR) have been widely used in treatment of metabolic syndromes and related disease, including nonalcoholic fatty liver disease (NAFLD). This study was designed to investigate lipid regulation effects of raw and processed NRR in steatotic L02 cell. Materials and Methods. Steatotic L02 cells were obtained after being cultured with 5% fat emulsion-10% FBS-RPMI 1640 medium for 48 h. Contents of total cholesterol (TC), triglyceride (TG), free fatty acid (FFA), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) in steatotic L02 cells were evaluated after treatment. Furthermore, the lipid metabolism regulation mechanism of Panax notoginseng saponins (PNS) and its monomers were evaluated by detecting the expressions of hydroxymethyl glutaric acyl coenzyme A reductase (HMG-CoAR), sterol regulating element binding protein-2 (SREBP-2), and cholesterol 7α-hydroxylase (CYP7α). Results. TG and TC contents were doubled in model group compared to those in normal L02 cells group. Raw NRR and NRR heated with sand (NRR-B) showed much remarkable lipid-lowering effects in steatotic L02 cells. PNS, notoginsenoside R1, ginsenoside Rg1, and ginsenoside Rb1 displayed the best TG and TC regulation activity, which could significantly reduce contents of SREBP-2 and HMG-CoAR and increase the content of CYP7α. Conclusions. Our results may support the fact that both raw NRR and NRR-B might have more satisfactory effects in the treatment of NAFLD.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27642594 PMCID: PMC5013208 DOI: 10.1155/2016/2919034
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Photographs of Notoginseng Radix Et Rhizome and its processed products: (a) NRR, (b) NRR-A, (c) NRR-B, and (d) NRR-C.
The percentage of notoginsenoside R1, ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1, and ginsenoside Rd in Notoginseng Radix Et Rhizome and its processed products.
| Sample | Notoginsenoside R1 | Ginsenoside Rg1 | Ginsenoside Re | Ginsenoside Rb1 | Ginsenoside Rd |
|---|---|---|---|---|---|
| NRR | 0.98 | 3.27 | 0.38 | 2.72 | 0.66 |
| NRR-A | 0.79 | 2.69 | 0.33 | 2.49 | 0.61 |
| NRR-B | 0.30 | 1.15 | 0.11 | 1.00 | 0.24 |
| NRR-C | 1.09 | 2.56 | 0.18 | 2.44 | 0.57 |
The contents of notoginsenoside R1, ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1, and ginsenoside Rd were analysed by HPLC as described in the text. NRR, Notoginseng Radix Et Rhizome; NRR-A, steamed NRR; NRR-B, NRR heated with sand; NRR-C, NRR fried with sesame oil.
Contents of TG in raw and processed NRR treated steatotic L02 cells.
| Sample | 10 | 20 | 40 | 80 | 100 |
|---|---|---|---|---|---|
| NRR | 0.40 ± 0.03 | 0.41 ± 0.00 | 0.48 ± 0.05 | 0.51 ± 0.00 | 0.36 ± 0.03 |
| NRR-A | 0.42 ± 0.00 | 0.38 ± 0.01 | 0.45 ± 0.02 | 0.44 ± 0.01 | 0.50 ± 0.03 |
| NRR-B | 0.44 ± 0.01 | 0.41 ± 0.01 | 0.39 ± 0.05 | 0.39 ± 0.03 | 0.38 ± 0.05 |
| NRR-C | 0.44 ± 0.04 | 0.48 ± 0.07 | 0.42 ± 0.04 | 0.55 ± 0.01 | 0.50 ± 0.02 |
| Control group | 0.25 ± 0.01### | ||||
| Model group | 0.53 ± 0.01 | ||||
| Lovastatin | 0.31 ± 0.01### | ||||
| Fenofibrate | 0.30 ± 0.01### |
Triglyceride (TG) contents were assayed by assay kits as described in the text. Values were mean ± SD (n = 3) and expressed in mmol/L. NRR, Notoginseng Radix Et Rhizome; NRR-A, steamed NRR; NRR-B, NRR heated with sand; NRR-C, NRR fried with sesame oil. NRR and its processed products were dissolved in 50% ethanol. ∗ indicates a significant difference compared with control group cells, and # indicates a significant difference compared with model group cells.
p < 0.001. # p < 0.05. ## p < 0.01. ### p < 0.001.
Contents of TC in raw and processed NRR treated steatotic L02 cells.
| Sample | 10 | 20 | 40 | 80 | 100 |
|---|---|---|---|---|---|
| NRR | 0.12 ± 0.01### | 0.14 ± 0.00### | 0.13 ± 0.01### | 0.13 ± 0.00### | 0.13 ± 0.00### |
| NRR-A | 0.16 ± 0.00 | 0.18 ± 0.01 | 0.13 ± 0.01### | 0.15 ± 0.01### | 0.14 ± 0.01### |
| NRR-B | 0.14 ± 0.00### | 0.15 ± 0.01### | 0.17 ± 0.01 | 0.16 ± 0.01 | 0.16 ± 0.01### |
| NRR-C | 0.13 ± 0.01### | 0.18 ± 0.01 | 0.13 ± 0.00### | 0.18 ± 0.01 | 0.18 ± 0.01 |
| Control group | 0.13 ± 0.01### | ||||
| Model group | 0.23 ± 0.00 | ||||
| Lovastatin | 0.12 ± 0.00 | ||||
| Fenofibrate | 0.13 ± 0.01 |
Total cholesterol (TC) contents were assayed by assay kits as described in the text. Values were mean ± SD (n = 3) and expressed in mmol/L. NRR, Notoginseng Radix Et Rhizome; NRR-A, steamed NRR; NRR-B, NRR heated with sand; NRR-C, NRR fried with sesame oil. NRR and its processed products were dissolved in 50% ethanol. ∗ indicates a significant difference compared with control group cells, and # indicates a significant difference compared with model group cells.
p < 0.05. p < 0.001. ### p < 0.001.
Contents of HDL-C in raw and processed NRR treated steatotic L02 cells.
| Sample | 10 | 20 | 40 | 80 | 100 |
|---|---|---|---|---|---|
| NRR | 0.33 ± 0.03 | 0.29 ± 0.02 | 0.30 ± 0.03 | 0.32 ± 0.01 | 0.33 ± 0.01 |
| NRR-A | 0.28 ± 0.04 | 0.26 ± 0.04 | 0.23 ± 0.04 | 0.22 ± 0.01 | 0.32 ± 0.03 |
| NRR-B | 0.41 ± 0.02## | 0.33 ± 0.04 | 0.31 ± 0.01 | 0.33 ± 0.05 | 0.31 ± 0.02 |
| NRR-C | 0.27 ± 0.02 | 0.26 ± 0.02 | 0.26 ± 0.01 | 0.26 ± 0.02 | 0.23 ± 0.04 |
| Control group | 0.42 ± 0.02### | ||||
| Model group | 0.22 ± 0.03 | ||||
| Lovastatin | 0.25 ± 0.31 | ||||
| Fenofibrate | 0.21 ± 0.03 |
High-density lipoprotein cholesterol (HDL-C) contents were assayed by assay kits as described in the text. Values were mean ± SD (n = 3) and expressed in mmol/L. NRR, Notoginseng Radix Et Rhizome; NRR-A, steamed NRR; NRR-B, NRR heated with sand; NRR-C, NRR fried with sesame oil. NRR and its processed products were dissolved in 50% ethanol. ∗ indicates a significant difference compared with control group cells, and # indicates a significant difference compared with model group cells.
p < 0.01. p < 0.001. # p < 0.05. ## p < 0.01. ### p < 0.001.
Contents of LDL-C in raw and processed NRR treated steatotic L02 cells.
| Sample | 10 | 20 | 40 | 80 | 100 |
|---|---|---|---|---|---|
| NRR | 1.48 ± 0.16### | 1.43 ± 0.19### | 1.51 ± 0.14### | 1.33 ± 0.08### | 1.56 ± 0.08### |
| NRR-A | 1.63 ± 0.12 | 1.87 ± 0.02 | 1.47 ± 0.22### | 1.47 ± 0.13### | 1.73 ± 0.13 |
| NRR-B | 1.19 ± 0.11### | 1.27 ± 0.08### | 1.32 ± 0.12### | 1.40 ± 0.21### | 1.21 ± 0.09### |
| NRR-C | 1.70 ± 0.11 | 1.75 ± 0.19 | 1.81 ± 0.19 | 1.83 ± 0.20 | 2.32 ± 0.06 |
| Control group | 2.40 ± 0.12### | ||||
| Model group | 1.23 ± 0.10 | ||||
| Lovastatin | 1.73 ± 0.12### | ||||
| Fenofibrate | 1.54 ± 0.22### |
Low-density lipoprotein cholesterol (LDL-C) contents were assayed by assay kits as described in the text. Values were mean ± SD (n = 3) and expressed in mmol/L. NRR, Notoginseng Radix Et Rhizome; NRR-A, steamed NRR; NRR-B, NRR heated with sand; NRR-C, NRR fried with sesame oil. NRR and its processed products were dissolved in 50% ethanol. ∗ indicates a significant difference compared with control group cells, and # indicates a significant difference compared with model group cells.
p < 0.01. p < 0.001. ## p < 0.01. ### p < 0.001.
Contents of FFA in raw and processed NRR treated steatotic L02 cells.
| Sample | 10 | 20 | 40 | 80 | 100 |
|---|---|---|---|---|---|
| NRR | 713.91 ± 69.25 | 484.53 ± 25.77### | 465.63 ± 41.66### | 398.62 ± 47.67### | 386.59 ± 15.46### |
| NRR-A | 577.32 ± 32.19 | 493.13 ± 82.53### | 513.75 ± 47.89## | 487.11 ± 27.57## | 505.15 ± 14.58## |
| NRR-B | 539.52 ± 24.36 | 613.4 ± 62.96 | 637.46 ± 61.06 | 525.77 ± 5.15 | 436.43 ± 31.5### |
| NRR-C | 582.47 ± 96.57 | 652.92 ± 12.97 | 673.54 ± 39.03 | 656.36 ± 75.99 | 817.87 ± 56.78 |
| Control group | 386.60 ± 5.15### | ||||
| Model group | 762.89 ± 52.31 | ||||
| Lovastatin | 680.41 ± 8.93 | ||||
| Fenofibrate | 639.18 ± 94.47 |
Free fatty acid (FFA) contents were assayed by assay kits as described in the text. Values were mean ± SD (n = 3) and expressed in mmol/L. NRR, Notoginseng Radix Et Rhizome; NRR-A, steamed NRR; NRR-B, NRR heated with sand; NRR-C, NRR fried with sesame oil. NRR and its processed products were dissolved in 50% ethanol. ∗ indicates a significant difference compared with control group cells, and # indicates a significant difference compared with model group cells.
p < 0.05. p < 0.01. p < 0.001. # p < 0.05. ## p < 0.01. ### p < 0.001.
Figure 2TG and TC contents in the steatotic L02 cells after treatment of triterpenoid saponins. Triglyceride (TG) (a) and total cholesterol (TC) (b) contents were assayed by assay kits as described in the text. Values were mean ± SD (n = 3) and expressed in mmol/L. NRR, Notoginseng Radix Et Rhizome; PNS, Panax notoginsenosides. ∗ indicates a significant difference compared with control group cells, and # indicates a significant difference compared with model group cells. p < 0.01. p < 0.001. ## p < 0.01. ### p < 0.001.
Figure 3CYP7α, HMG-CoAR, and SREBP-2 contents in the steatotic L02 cells after treatment of triterpenoid saponins. CYP7α (a), HMG-CoAR (b), and SREBP-2 (c) contents were assayed by assay kits as described in the text. Values were mean ± SD (n = 3) and expressed in mmol/L. PNS, Panax notoginsenosides. ∗ indicates a significant difference compared with control group cells, and # indicates a significant difference compared with model group cells. p < 0.05. p < 0.01. p < 0.001. ## p < 0.01. ### p < 0.001.